Terui H, Asano M, Shimada-Omori R, et al. - This study’s findings demonstrate that before treatment, these three clinical features of BMI, HbA1c, and serum CRP level are the predictors of successful infliximab (IFX) treatment and imply that improvement of metabolic conditions contributes to avoiding secondary failure and discontinuance of IFX.

• Researchers designed a retrospective, single-center, case-control study including a total of 34 patients.

• In this study, 7 patients who discontinued IFX because of adverse events of IFX were excluded.

• Other 27 patients were categorized into two groups; 16 patients who kept using IFX (Continuance group); and 11 patients who switched to other treatments (Discontinuance group).

• Compared with the Continuance group, body mass index (BMI), HbA1c, and serum CRP level were significantly higher in the Discontinuance group among various clinical features.